Histone deacetylase activity is potently inhibited by hydroaximc acid derivatives such as suberoylanilide hydroxamic acid (SARA) and trichostatin-A (TSA). These inhibitors specifically induce differentiation/apoptosis of transformed cells in vitro and suppress tumor growth in vivo. Because of its low toxicity, SARA is currently evaluated in clinical trials for the treatment of cancer. SARA and TSA induce apoptosis, which is characterized by mitochondrial stress, but so far, the critical elements of this apoptotic program remain poorly defined. To characterize in more detail this apoptotic program, we used human cell lines containing alterations in important elements of apoptotic response such as: p53, Bcl-2, caspase-9, and caspase-3. We dem...
Several studies in the last years evidenced that deregulation of proapoptotic and antiapoptotic path...
PubMed ID: 18419600Many studies aim at improving therapeutic efficacy by combining strategies with o...
Histone deacetylase inhibitors (HDACIs)-based therapies have stimulated interest via their anti-tumo...
Histone deacetylase activity is potently inhibited by hydroaximc acid derivatives such as suberoylan...
Histone deacetylase inhibitors (HDACIs) activate genes that promote cell cycle arrest and apoptosis ...
HDAC1 (Histone deacetylase) activity is inhibited by 9-hydroxystearic acid (9-HSA) (1,2). HDAC1 inhi...
Autophagy is an essential process of the eukaryotic cell allowing degradation and recycling of dysfu...
This report shows that histone deacetylase inhibitors (HDACIs) induced apoptosis in human hepatoma H...
Histone deacetylase (HDAC) inhibitors represent a promising group of anticancer agents. This paper s...
Histone deacetylase inhibitors (HDACis) are antineoplastic agents that affect cell growth, different...
9-hydroxystearic acid (9-HSA) belongs to the class of endogenous lipid peroxidation by-products that...
This paper shows that the histone deacetylase inhibitor SAHA sensitised at sub-toxic doses human hep...
SAHA (suberoylanilide hydroxamic acid or vorinostat) is the first nonselective histone deacetylase (...
Aim: Histone deacetylase inhibitors (HDACIs)-based therapies have stimulated interest via their anti...
Several studies in the last years evidenced that deregulation of proapoptotic and antiapoptotic path...
PubMed ID: 18419600Many studies aim at improving therapeutic efficacy by combining strategies with o...
Histone deacetylase inhibitors (HDACIs)-based therapies have stimulated interest via their anti-tumo...
Histone deacetylase activity is potently inhibited by hydroaximc acid derivatives such as suberoylan...
Histone deacetylase inhibitors (HDACIs) activate genes that promote cell cycle arrest and apoptosis ...
HDAC1 (Histone deacetylase) activity is inhibited by 9-hydroxystearic acid (9-HSA) (1,2). HDAC1 inhi...
Autophagy is an essential process of the eukaryotic cell allowing degradation and recycling of dysfu...
This report shows that histone deacetylase inhibitors (HDACIs) induced apoptosis in human hepatoma H...
Histone deacetylase (HDAC) inhibitors represent a promising group of anticancer agents. This paper s...
Histone deacetylase inhibitors (HDACis) are antineoplastic agents that affect cell growth, different...
9-hydroxystearic acid (9-HSA) belongs to the class of endogenous lipid peroxidation by-products that...
This paper shows that the histone deacetylase inhibitor SAHA sensitised at sub-toxic doses human hep...
SAHA (suberoylanilide hydroxamic acid or vorinostat) is the first nonselective histone deacetylase (...
Aim: Histone deacetylase inhibitors (HDACIs)-based therapies have stimulated interest via their anti...
Several studies in the last years evidenced that deregulation of proapoptotic and antiapoptotic path...
PubMed ID: 18419600Many studies aim at improving therapeutic efficacy by combining strategies with o...
Histone deacetylase inhibitors (HDACIs)-based therapies have stimulated interest via their anti-tumo...